cervical carcinoma cell

Pritumumab, a natural human IgG1kappa monoclonal antibody (mAb), was first isolated from the regional draining lymph node of a cervical carcinoma patient. It specifically recognizes cell-surface-expressed vimentin on malignant tumors and has applications in glioblastoma research [1] [2].

Socazolimab (ZKAB001), an anti-PD-L1 monoclonal antibody, demonstrates enduring safety and efficacy in treating recurrent or metastatic cervical cancer. Additionally, it shows promise for treating small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma, and osteosarcoma [1] [2] [3] [4] [5].

Lirilumab (IPH2102) is an antibody against the lethal immunoglobulin-like receptor antibody KIR2D with antitumor activity that enhances the anti-HPV + cervical cancer activity of natural killer cells through VAV1-dependent NF-κB deinhibition. It can be used to study leukemia, head and neck squamous cell carcinoma (SCCHN).